Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | VNN1 | O95497 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL11262863 | 0.98 | ATM (0.61) | ATMTDP1L3MBTL1AKR1B1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11844165 | 0.98 | ATM (0.61) | ATMTDP1L3MBTL1AKR1B1ALDH1A1 | |
| Methane SCHEMBL11257402 | 0.96 | ATM (0.59) | ATMTDP1L3MBTL1AKR1B1ALDH1A1 | |
| SCHEMBL19202273 | 0.96 | AKR1B1 (0.58) | ATMTDP1L3MBTL1AKR1B1PBRM1 | |
| SCHEMBL19202271 | 0.91 | AKR1B1 (0.52) | ATMTDP1L3MBTL1AKR1B1PBRM1 | |
| SCHEMBL9427627 | 0.90 | CYP19A1 (0.53) | ATMTDP1L3MBTL1AKR1B1SRD5A2 | |
| SCHEMBL15717569 | 0.88 | SRD5A2 (0.59) | ATMTDP1L3MBTL1AKR1B1SRD5A2 | |
| SCHEMBL11445035 | 0.88 | L3MBTL1 (0.51) | ATMTDP1L3MBTL1AKR1B1SRD5A2 | |
| Benzophenone SCHEMBL8820654 | 0.88 | AKR1B1 (0.77) | ATMTDP1L3MBTL1AKR1B1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11541768 | 0.87 | L3MBTL1 (0.50) | ATMTDP1L3MBTL1AKR1B1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | claimed |
| EP-1309323-B1 | TREATMENT OF ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID DERIVATIVES | ALCON INC (CH) | 2006-11-15 | — | — | EP | claimed |
| EP-1309322-B1 | USE OF 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISORDERS | ALCON INC (CH) | 2006-06-21 | — | — | EP | claimed |
| JP-2004520267-A | — | — | 2004-07-08 | — | — | JP | claimed |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALCON, INC. (CH) | 2004-07-08 | — | — | US | claimed |
| US-6638976-B2 | 3-benzoylphenylacetic acids and derivatives, including nepafenac, to treat neurodegenerative retinal disorders | ALCON, INC. (CH) | 2003-10-28 | — | — | US | claimed |
| CN-1447688-A | Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid | ALCON UNIVERSAL LTD (CH) | 2003-10-08 | — | — | CN | claimed |
| US-20030187072-A1 | Method of treating angiogenesis-related disorders | ALCON, INC. (CH) | 2003-10-02 | — | — | US | claimed |
| EP-1309322-A2 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS OF THE RETINA AND OPTIC NERVE HEAD | Alcon, Inc (CH) | 2003-05-14 | — | — | EP | claimed |
| EP-1309323-A2 | METHOD OF TREATING ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID | Alcon Inc. (CH) | 2003-05-14 | — | — | EP | claimed |
| US-20020049255-A1 | Method of treating neurodegenerative disorders of the retina and optic nerve head | ALCON UNIVERSAL LTD. | 2002-04-25 | — | — | US | claimed |
| EP-0716600-B1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LAB INC (US) | 2002-04-03 | — | — | EP | claimed |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | ALCON UNIVERSAL LTD. | 2002-03-28 | — | — | US | claimed |
| WO-2002013805-A2 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS OF THE RETINA AND OPTIC NERVE HEAD | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | claimed |
| WO-2002013804-A2 | METHOD OF TREATING ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | claimed |
| EP-0525506-B2 | A process for the alpha-monoalkylation of arylacetonitriles, arylacetoesters and arylacetic acids | TESSENDERLO CHEM NV (BE) | 1999-03-17 | — | — | EP | claimed |
| CN-1129397-A | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 1996-08-21 | — | — | CN | claimed |
| EP-0716600-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1995033457-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-5475034-A | Adminstering 3-benzoylphenylacetamide derivatives | ALCON LABORATORIES, INC. (US) | 1995-12-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049255-A1 | Method of treating neurodegenerative disorders of the retina and optic nerve head | NLN, ALDH1A2, GAP43 | ATM 4547/4885TDP1 448/4885L3MBTL1 3367/4885 |
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | FLT1, TEK, FLT4 | ATM 1529/4885TDP1 3768/4885L3MBTL1 4733/4885 |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALDH1A2, GAP43, NLN | ATM 4644/4885TDP1 480/4885L3MBTL1 3511/4885 |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | MME, FLT4, EYA3 | ATM 4669/4885TDP1 2956/4885L3MBTL1 2897/4885 |
| US-20030187072-A1 | Method of treating angiogenesis-related disorders | MME, FLT4, EYA3 | ATM 4669/4885TDP1 2956/4885L3MBTL1 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.